Health News

SILVER SPRING, Md. (MedPage Today) — The FDA’s advisory panel on cancer drugs recommended accelerated approval for bevacizumab (Avastin) as a treatment for glioblastoma multiforme, the notoriously deadly form of brain cancer.

Read more

Filed under: Pharmacy News
Tags: brain, cancer, Drug, Pharmacy

Related posts

• Scientists to develop methotrexate nose drops for brain cancer (0)
  Scientists are reporting the development and successful initial testing of a new form of methotrexate the mainstay anticancer drug designed to be given as nose drops rather than injected. It shows promise as a more effective treatment for brain cancer, they say. The report appears in ACS' Molecular Pharmaceutics, a bi-monthly journal. Read more [tags] Pharmacy News [...]
  
  
• Researcher tackles deadly brain tumors (0)
  Natalie Ciaccio, a fourth-year graduate student researcher in the Department of Pharmaceutical Chemistry at the University of Kansas, is investigating what might be an ideal target for anti-cancer drug therapy, and she is focusing her work on brain tumors specifically. Read more [tags] Pharmacy News [/tags]
  
  
• Hydrophilic carbon cluster HADES can selectively kill brain cancer cells (0)
  Nanomedicine researchers at the Methodist Neurological Institute and Rice University have developed a way to selectively kill brain cancer cells by using a tiny syringe to deliver a combination of chemotherapy drugs directly into the cells. These findings will be published in the April 24 issue of the American Chemical Society journal ACS Nano. Read more [tags] [...]
  
  
• Genentech’s Hedgehog Signal Inhibitor Helped Patients With Advanced Skin And Brain Cancers (0)
  A new type of experimental anti-cancer drug developed by Genentech, which inhibits the hedgehog signalling pathway, was effective in treating patients with advanced skin cancer. It was also very effective at first in treating a patient with an advanced type of brain cancer, and initial results were [...]
  
  
• Genentech submits application to FDA for Avastin in the most aggressive form of brain cancer (0)
  Genentech has announced that the company submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for Avastin (bevacizumab) as a therapy for people with previously treated glioblastoma. If accepted by the FDA, the application would be considered for an accelerated approval that allows provisional approval of medicines for cancer [...]